Clinical Nutrition Market to reach $80 billion by 2024
Get more details @ http://bit.ly/2oBj4cQ Few players dominate clinical nutrition market such as Abbott Laboratories, Nestle, Danone, Fresenius Kabi, Hospira, Perrigo, B Braun Melsungen, Baxter International and Mead Johnson. Product development, strategic alliances and consolidating across the distribution channel remain key commercial strategies adopted by industry participants. Industry participants are also expanding their operations in emerging economies to gain extended market access and strengthen their market position.
Get more details @ http://bit.ly/2oBj4cQ
Few players dominate clinical nutrition market such as Abbott Laboratories, Nestle, Danone, Fresenius Kabi, Hospira, Perrigo, B Braun Melsungen, Baxter International and Mead Johnson. Product development, strategic alliances and consolidating across the distribution channel remain key commercial strategies adopted by industry participants. Industry participants are also expanding their operations in emerging economies to gain extended market access and strengthen their market position.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4 | P a g e<br />
3.3.1 Distribution channel analysis<br />
3.4 Industry impact forces<br />
3.4.1 Growth Drivers<br />
3.4.1.1 Increasing metabolic disorders and other chronic diseases<br />
3.4.1.2 Junk food habits leading <strong>to</strong> malnourishment in U.S. &<br />
Europe<br />
3.4.1.3 Increasing geriatric population<br />
3.4.1.4 Increasing rate of pre-mature birth & birth rate in APAC<br />
3.4.1.5 Increasing adoption of home healthcare in North America<br />
and Europe<br />
3.4.2 Industry pitfalls & Challenges<br />
3.4.2.1 Stringent government regulations in U.S., Europe, and<br />
APAC<br />
3.4.2.2 Lack of awareness regarding nutrition in developing<br />
countries<br />
3.5 Growth potential analysis<br />
3.6 Regula<strong>to</strong>ry landscape<br />
3.6.1 U.S.<br />
3.6.2 Europe<br />
3.6.3 China<br />
3.7 Reimbursement scenario<br />
3.7.1 U.S.<br />
3.7.2 Europe<br />
3.8 Pipeline analysis<br />
3.9 Pricing analysis<br />
3.9.1 North America
Change language